附件99.1

Akari治療公司宣佈提供900萬美元的直接註冊服務

紐約和倫敦，2022年3月8日-阿卡里 治療公司(納斯達克代碼：aktx)(以下簡稱阿卡里公司)今天宣佈，它已經與某些機構投資者、認可投資者以及阿卡里公司的Ray Prudo博士達成了最終協議。阿卡里公司專注於創新的 療法來治療涉及補體和/或白三烯系統的孤兒自身免疫性和炎症性疾病。 阿卡里公司 今天宣佈，它已經與某些機構投資者、經認可的投資者以及阿卡里公司的Ray Prudo博士達成了最終協議。 阿卡里公司專注於創新的 療法來治療涉及補體和/或白三烯系統的孤兒自身免疫性和炎症性疾病

關於此次發行，公司將 以每美國存托股份1.2美元的收購價 直接發行約7,500,000股阿卡里的註冊美國存托股票(ADS)。此外，投資者每購買一個美國存托股份，就會獲得一個註冊認股權證，可以購買一個美國存托股份的一半 。這些認股權證的行使價為每張美國存托股份1.4美元，可在發行時行使，自發行之日起五年內到期 。此次發行預計將於2022年3月10日左右結束，條件是滿足慣例的成交條件 。

保爾森投資公司(Paulson Investment Company，LLC)將擔任此次發行的獨家配售代理。

上述證券是由阿卡利根據之前於2020年12月23日提交給美國證券交易委員會(以下簡稱“美國證券交易委員會”)並於2020年12月31日由美國證券交易委員會宣佈生效的F-3表格(第333-251673號文件)中的有效擱置登記聲明而發售的。證券的發售將僅通過招股説明書的方式進行，包括招股説明書附錄，構成有效註冊聲明的一部分 。

本公司將 提交與所發行證券有關的招股説明書補充文件及隨附的基礎招股説明書及美國證券交易委員會。上市後，招股説明書附錄和隨附的基本招股説明書的電子版可在美國證券交易委員會網站http://www.sec.gov， 獲取，也可聯繫小唐納德·A·沃伊諾斯基獲取。電話：(855)653-3444或電子郵件：dwojnowski@paulsoninvestment.com。

本新聞稿不構成出售或邀請購買本文所述任何證券的要約 。根據任何州或司法管轄區的證券法，在 註冊或資格登記或資格之前，不得在任何州或司法管轄區進行任何要約、 要約購買或出售證券，在這些州或司法管轄區，此類發售、招攬或出售將是非法的。

關於阿卡里治療公司

Akari是一家生物製藥公司，專注於 開發急性和慢性炎症抑制劑，專門用於治療罕見和孤兒疾病，特別是那些補體(C5)或白三烯(LTB4)系統，或補體和白三烯共同在疾病進展中起主要作用的疾病 。Akari的主要候選藥物Nomacopan(以前稱為Coversin)是一種C5補體抑制劑，也獨立地 並特異性地抑制白三烯B4(LTB4)的活性。Nomacopan目前正在四個領域進行臨牀評估：大皰性類天皰瘡 (BP)、血栓性微血管病(TMA)以及眼部和肺部項目。

有關前瞻性陳述的注意事項

Certain statements in this press release constitute “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995 regarding, among other things, statements related to the offering, the expected gross proceeds and the expected closing of the offering. These forward-looking statements reflect our current views about our plans, intentions, expectations, strategies and prospects, which are based on the information currently available to us and on assumptions we have made. Although we believe that our plans, intentions, expectations, strategies and prospects as reflected in or suggested by those forward-looking statements are reasonable, we can give no assurance that the plans, intentions, expectations or strategies will be attained or achieved. Furthermore, actual results may differ materially from those described in the forward-looking statements and will be affected by a variety of risks and factors that are beyond our control. Such risks and uncertainties for our company include, but are not limited to: needs for additional capital to fund our operations, our ability to continue as a going concern; uncertainties of cash flows and inability to meet working capital needs; an inability or delay in obtaining required regulatory approvals for Nomacopan and any other product candidates, which may result in unexpected cost expenditures; our ability to obtain orphan drug designation in additional indications; risks inherent in drug development in general; uncertainties in obtaining successful clinical results for Nomacopan and any other product candidates and unexpected costs that may result therefrom; difficulties enrolling patients in our clinical trials; our ability to enter into collaborative, licensing, and other commercial relationships and on terms commercially reasonable to us; failure to realize any value of Nomacopan and any other product candidates developed and being developed in light of inherent risks and difficulties involved in successfully bringing product candidates to market; inability to develop new product candidates and support existing product candidates; the approval by the U.S. Food and Drug Administration (FDA) and European Medicines Agency (EMA) and any other similar foreign regulatory authorities of other competing or superior products brought to market; risks resulting from unforeseen side effects; risk that the market for Nomacopan may not be as large as expected; risks associated with the impact of the COVID-19 pandemic; inability to obtain, maintain and enforce patents and other intellectual property rights or the unexpected costs associated with such enforcement or litigation; inability to obtain and maintain commercial manufacturing arrangements with third party manufacturers or establish commercial scale manufacturing capabilities; the inability to timely source adequate supply of our active pharmaceutical ingredients from third party manufacturers on whom the company depends; unexpected cost increases and pricing pressures and risks and other risk factors detailed in our public filings with the SEC, including our most recently filed Annual Report on Form 20-F filed with the SEC. Except as otherwise noted, these forward-looking statements speak only as of the date of this press release and we undertake no obligation to update or revise any of these statements to reflect events or circumstances occurring after this press release. We caution investors not to place considerable reliance on the forward-looking statements contained in this press release.